Who owns Sionna Therapeutics, Inc. (RNAI)? Elite investor 13F holders
2 tracked elite investors reported holding Sionna Therapeutics, Inc as of 2026-06-30, including Viking Global Investors, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Viking Global Investors | SIONNA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 140556012.00 USD | 3195181.000000 | Shares | hold | Original filing |
| D.E. Shaw | SIONNA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 4471320.00 USD | 101644.000000 | Shares | buy | Original filing |
| Polen Capital Management | SIONNA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.